Story
Oslo Børs Gains as Healthcare and Tech Stocks Outweigh Energy Sector Losses

Summary
Norway's benchmark Oslo OBX index rose 0.34% at Thursday's close, lifted by strong performance in healthcare and technology stocks which offset declines in major energy companies amid falling oil prices.
Norway's benchmark stock index, the Oslo OBX, finished Thursday's trading session in positive territory, climbing 0.34% despite pressure from declining energy shares. The advance was primarily driven by strong performance in the healthcare, life sciences, and utilities sectors, according to market data.
Sector Divergence Drives Market
The session was characterized by a clear divergence between sectors. Technology and healthcare-related companies were among the top performers, providing the main upward thrust for the index.
- Nordic Semiconductor ASA (OL:NOD) was the day's leading gainer, surging 4.41% to close at 158.60.
- Tomra Systems ASA (OL:TOM) followed, adding 3.24% to its share price.
- Subsea 7 SA (OL:SUBC) also posted a solid gain, rising 2.62%.
Overall market breadth was positive on the Oslo Stock Exchange, with 143 stocks advancing compared to 100 decliners, while 34 ended the session unchanged.
Energy Stocks Weigh on Index
AdIn contrast to the broader market gains, heavyweight energy stocks acted as a drag on the index. The decline in this sector coincided with a drop in global oil prices, with Brent crude for October delivery falling 1.06% to $87.16 a barrel.
Key energy sector losers included:
- Equinor ASA (OL:EQNR), which fell 2.29%.
- Var Energi ASA (OL:VAR), declining 1.25%.
Currency and Commodity Snapshot
In currency markets, the Norwegian krone showed mixed results. The EUR/NOK pair rose 0.17% to 11.01, while the USD/NOK pair fell 0.20% to 9.57, indicating a slight strengthening of the krone against the U.S. dollar. Elsewhere in commodities, Gold Futures for August delivery saw a significant increase, rising 1.53% to trade at $4,098.10 a troy ounce.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.